Replies to post #129037 on Biotech Values

[Biowatch]

"Trying To Beat The Odds In Pancreatic Cancer"
http://seekingalpha.com/article/301622-baker-s-dozen-trying-to-beat-the-odds-in-pancreatic-cancer

November marks Pancreatic Cancer Awareness Month. According to the American Cancer Society, more than 44,000 new cases of pancreatic cancer will be diagnosed in the U.S. and over 37,000 deaths are expected from the disease in 2011. It has the highest mortality rate of all major cancers;...

Visibility for the disease is on the rise following the recent deaths of Apple, Inc. (AAPL) co-founder Steve Jobs and Ralph Steinman, a cell biologist who died several days before being named one of three winners for the 2011 Nobel Prize in Medicine. While awareness is increasing, there is an urgent need for more effective treatments and diagnostics to detect the disease earlier due to the fact that the number of new pancreatic cancer cases is projected to increase by 55% from 2010 to 2030[3].

Article by Michael Becker about a "Baker's Dozen" of treatments.

Any thoughts on the drugs listed or the author?

 Table 1. Baker’s Dozen in Active Clinical Development for Pancreatic Cancer  
 [modified slightly to fit here better. 
 immuno = Immunotherapy 
 chemo = chemotherapy] 
  
 Company	Product	Class	[Clinical Trial] Stage 
 Aduro BioTech, Inc. (private)	Cancer Vaccines CRS-207 & GVAX Pancreas	Immuno	Ph II 
 Amgen (AMGN)	AMG 479	Immuno	Ph II 
 Celgene Corporation (CELG)	Abraxane	Chemo	Ph III 
 Celgene Corporation (CELG) & GlobeImmune (private)	GI-4000	Immuno	Ph II 
 Clovis Oncology, Inc. (private)	CO-101	Chemo	Ph II 
 Immunomedics (IMMU)	90Y-hPAM4	Radiopharmaceutical	 Ph Ib 
 Infinity Pharmaceuticals (INFI)	IPI-926	Signal transduction inhibitor	Ph Ib/II 
 NewLink Genetics Corporation (private)	HyperAcute®-Pancreas (Algenpantucel-L)	Immuno	Ph III 
 Novartis AG (NVS) & Bayer Schering Pharma AG (BAYRY.PK)	Vatalanib (PTK787/ZK-222584)	Kinase inhibitor	Ph I/II 
 Oncolytics Biotech (ONCY)	Reolysin®	Reovirus	Ph II 
 Pharmacyclics (PCYC)	PCI-27483	Signal transduction inhibitor	Ph II 
 Seattle Genetic. (SGEN) & Astellas Pharma (ALPMY.PK)	ASG-5ME	Immuno – drug conjugate	Ph I 
 Threshold Pharmaceuticals (THLD)	TH-302	Chemo	Ph II